{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-25-000022","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.344863+00:00","generated_at":"2026-05-22T04:51:54.462212+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada reports Q1 net loss of $17.3M, gets EU clearance for DMD exon 44 trial, cuts workforce 20%","bullets":["Net loss of $17.3M in Q1 2025 vs net income $23.5M Q1 2024; collaboration revenue fell to $20.6M from $59.1M.","EU authorization received for Phase 1/2 MAD study (ELEVATE-44-201) of ENTR-601-44; Q2 2025 initiation on track.","Additional DMD programs: ENTR-601-45 study initiation Q3 2025; ENTR-601-50 regulatory submission H2 2025.","Workforce reduced ~20% to focus on DMD clinical pipeline and key preclinical programs; cash runway into Q2 2027 ($382.5M).","Vertex-partnered VX-670 for DM1 continues enrollment in MAD portion of Phase 1/2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-25-000022","json":"https://secwatch.observer/filing/0001689375-25-000022.json","markdown":"https://secwatch.observer/filing/0001689375-25-000022.md","text":"https://secwatch.observer/filing/0001689375-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/0001689375-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/trda-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:51:54.462212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}